ReviewEndocrine2013
Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy.
Review in Endocrine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 60 citations in OpenAlex.
- Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide.Clinics (Sao Paulo, Brazil) · 2020Trial
- Apple Polyphenol Mitigates Diabetic Nephropathy via Attenuating Renal Dysfunction with Antioxidation in Streptozotocin-Induced Diabetic Rats.Antioxidants (Basel, Switzerland) · 2025Article
- Urinary cyclophilin A as an early marker of chronic kidney disease with underlying type 2 diabetes.Scientific reports · 2024Article
- Current update on theranostic roles of cyclophilin A in kidney diseases.Theranostics · 2022Review
- Impaired Glomerular Filtration Rate in Type 2 Diabetes Mellitus Subjects: A Nationwide Cross-Sectional Study in Thailand.Journal of diabetes research · 2020Article
- Gene expression-based analysis identified NTNG1 and HGF as biomarkers for diabetic kidney disease.Medicine · 2020Observational
- Cyclophilin A (CyPA) as a Novel Biomarker for Early Detection of Diabetic Nephropathy in an Animal Model.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- The effect of A1 adenosine receptor in diabetic megalin loss with caspase-1/IL18 signaling.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Effects of Chronic Administration of Capsaicin on Biomarkers of Kidney Injury in Male Wistar Rats with Experimental Diabetes.Molecules (Basel, Switzerland) · 2018Article
- Systems biology approaches to identify disease mechanisms and facilitate targeted therapy in the management of glomerular disease.Current opinion in nephrology and hypertension · 2018Review
- Assessment of Vitamin D-Binding Protein and Early Prediction of Nephropathy in Type 2 Saudi Diabetic Patients.Journal of diabetes research · 2018Article
- Tubulointerstitial Biomarkers for Diabetic Nephropathy.Journal of diabetes research · 2018Review
- A more tubulocentric view of diabetic kidney disease.Journal of nephrology · 2017Review
- Development of a Functional Glomerulus at the Organ Level on a Chip to Mimic Hypertensive Nephropathy.Scientific reports · 2016Article
- Adipokine zinc-alpha-2-glycoprotein as a novel urinary biomarker presents earlier than microalbuminuria in diabetic nephropathy.The Journal of international medical research · 2016Observational
- Urinary Cyclophilin A as a New Marker for Diabetic Nephropathy: A Cross-Sectional Analysis of Diabetes Mellitus.Medicine · 2015Observational
- Routine kidney variables, glomerular filtration rate and urinary cystatin C in cats with diabetes mellitus, cats with chronic kidney disease and healthy cats.Journal of feline medicine and surgery · 2015Article
- Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients.Diabetes & metabolism journal · 2015Article
- Low protein diet inhibits uric acid synthesis and attenuates renal damage in streptozotocin-induced diabetic rats.Journal of diabetes research · 2014Article
- Zinc alpha 2 glycoprotein as an early biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The prevalence of diabetic nephropathy has tremendously increased with the relentless rise in the incidence of diabetes over the last couple decades. Diabetic nephropathy is a leading cause of morbidity and mortality, and it invariably leads to an end-stage renal disease (ESRD). In an effort to delay the onset of ESRD systematic screening and appropriate management are needed to evaluate the progression of renal damage in diabetic nephropathy. The reliability of current tests in predicting the onset, progression and response to various regimens for diabetic nephropathy is still under debate; and it has engendered a search for more sensitive and specific urinary biomarkers, especially those reflective of tubular dysfunctions. It is well-known that there is a good correlation between the degree of damage to the tubulo-interstitial compartment and the deterioration of renal functions. In view of this, the utility of urinary biomarkers, reflective of tubular injury, reported in the literature is discussed in this brief review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.